Literature DB >> 17611563

Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation.

B Oran, S Giralt, D Couriel, C Hosing, E J Shpall, E de Meis, I F Khouri, M Qazilbash, P Anderlini, P Kebriaei, U Popat, A Carrasco-Yalan, R E Champlin, M de Lima.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17611563     DOI： 10.1038/sj.leu.2404828

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  23 in total

1.  Second allogeneic transplantation for relapsed acute leukemia after initial allogeneic hematopoietic stem cell transplantation.

Authors:  Ryo Hanajiri; Kazuteru Ohashi; Yuka Hirashima; Kazuhiko Kakihana; Takeshi Kobayashi; Takuya Yamashita; Hisashi Sakamaki; Hideki Akiyama
Journal:  Pathol Oncol Res       Date:  2012-04-29       Impact factor: 3.201

Review 2.  Reduced-intensity conditioned allogeneic SCT in adults with AML.

Authors:  R Reshef; D L Porter
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

3.  Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.

Authors:  Marcos de Lima; Sergio Giralt; Peter F Thall; Leandro de Padua Silva; Roy B Jones; Krishna Komanduri; Thomas M Braun; Hoang Q Nguyen; Richard Champlin; Guillermo Garcia-Manero
Journal:  Cancer       Date:  2010-07-29       Impact factor: 6.860

4.  Low incidence of GvHD with T-cell depleted allografts facilitates further treatments for post-transplantation relapse in AML and MDS.

Authors:  P B Dahi; E Morawa; M-A Perales; E C Zabor; S M Devlin; M Maloy; H Castro-Malaspina; R J O'Reilly; E B Papadopoulos; A A Jakubowski; S A Giralt
Journal:  Bone Marrow Transplant       Date:  2016-02-29       Impact factor: 5.483

5.  Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes.

Authors:  R Vrhovac; M Labopin; F Ciceri; J Finke; E Holler; J Tischer; B Lioure; J Gribben; L Kanz; D Blaise; P Dreger; G Held; R Arnold; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2015-10-05       Impact factor: 5.483

6.  Infusion of donor-derived CD8+ memory T cells for relapse following allogeneic hematopoietic cell transplantation.

Authors:  Lori Muffly; Kevin Sheehan; Randall Armstrong; Kent Jensen; Keri Tate; Andrew R Rezvani; David Miklos; Sally Arai; Judith Shizuru; Laura Johnston; Everett Meyer; Wen-Kai Weng; Ginna G Laport; Robert S Negrin; Sam Strober; Robert Lowsky
Journal:  Blood Adv       Date:  2018-03-27

7.  Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.

Authors:  Manish Sharma; Farhad Ravandi; Ulas Darda Bayraktar; Alexandre Chiattone; Qaiser Bashir; Sergio Giralt; Julianne Chen; Muzaffar Qazilbash; Partow Kebriaei; Marina Konopleva; Michael Andreeff; Jorge Cortes; Deborah McCue; Hagop Kantarjian; Richard E Champlin; Marcos de Lima
Journal:  Biol Blood Marrow Transplant       Date:  2011-07-20       Impact factor: 5.742

Review 8.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation.

Authors:  Steven Z Pavletic; Shaji Kumar; Mohamad Mohty; Marcos de Lima; James M Foran; Marcelo Pasquini; Mei-Jie Zhang; Sergio Giralt; Michael R Bishop; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2010-04-24       Impact factor: 5.742

9.  Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia.

Authors:  Elias Jabbour; Sergio Giralt; Hagop Kantarjian; Guillermo Garcia-Manero; Madan Jagasia; Partow Kebriaei; Leandro de Padua; Elizabeth J Shpall; Richard Champlin; Marcos de Lima
Journal:  Cancer       Date:  2009-05-01       Impact factor: 6.860

10.  Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.

Authors:  Iskra Pusic; Jaebok Choi; Mark A Fiala; Feng Gao; Matthew Holt; Amanda F Cashen; Ravi Vij; Camille N Abboud; Keith E Stockerl-Goldstein; Meghan A Jacoby; Geoffrey L Uy; Peter Westervelt; John F DiPersio
Journal:  Biol Blood Marrow Transplant       Date:  2015-06-05       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.